Amgen Inc. Impairment of Intangible Assets (Excluding Goodwill)
Amgen Inc. (AMGN) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-08-05
- Amgen Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2026-06-30 was $0.00.
- Amgen Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-30 was $400.00M, a 555.74% increase year-over-year.
- Amgen Inc. impairment of intangible assets (excluding goodwill) for fiscal 2025 was $1.20B, a 654.72% increase from fiscal 2024.
- Amgen Inc. impairment of intangible assets (excluding goodwill) for fiscal 2024 was $159.00M, a 81.32% decline from fiscal 2023.
- Amgen Inc. impairment of intangible assets (excluding goodwill) for fiscal 2023 was $851.00M.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $400.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-05-01 | $400.00M derived: sum of 3 quarters · filed 2026-05-01 | $400.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $400.00M derived: sum of 2 quarters · filed 2026-02-13 | $400.00M derived: sum of 3 quarters · filed 2026-08-05 | $1.20B 10-K · filed 2026-02-13 |
| 2025-09-30 | $400.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $400.00M derived: sum of 2 quarters · filed 2026-08-05 | $1.20B 10-Q · filed 2025-11-05 | $1.23B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $800.00M 10-Q · filed 2026-08-05 | $830.00M derived: sum of 3 quarters · filed 2026-08-05 | $891.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $800.00M 10-Q · filed 2026-05-01 | $830.00M derived: sum of 2 quarters · filed 2026-05-01 | $891.00M derived: sum of 3 quarters · filed 2026-05-01 | $891.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $91.00M derived: sum of 2 quarters · filed 2026-02-13 | $91.00M derived: sum of 3 quarters · filed 2026-02-13 | $159.00M 10-K · filed 2026-02-13 |
| 2024-09-30 | $61.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $61.00M derived: sum of 2 quarters · filed 2025-11-05 | $129.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $68.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $68.00M 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | $851.00M 10-K · filed 2026-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |